Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The discovery and development of romidepsin for the treatment of T-cell lymphoma
Piotr Smolewski, Tadeusz Robak
Expert Opinion on Drug Discovery (2017), pp. 1-15
Closed Access | Times Cited: 70

Showing 1-25 of 70 citing articles:

Understanding Cell Penetration of Cyclic Peptides
Patrick G. Dougherty, Ashweta Sahni, Dehua Pei
Chemical Reviews (2019) Vol. 119, Iss. 17, pp. 10241-10287
Open Access | Times Cited: 445
Cancer prevention and treatment using combination therapy with natural compounds
Edward R. Sauter
Expert Review of Clinical Pharmacology (2020) Vol. 13, Iss. 3, pp. 265-285
Closed Access | Times Cited: 146
Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies
Ailin Zhao, Hui Zhou, Jinrong Yang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 60
MYC competes with MiT/TFE in regulating lysosomal biogenesis and autophagy through an epigenetic rheostat
Ida Annunziata, Diantha van de Vlekkert, Elmar Wolf, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 87
Bacteria as a treasure house of secondary metabolites with anticancer potential
Chakrabhavi Dhananjaya Mohan, Shobith Rangappa, S. Chandra Nayak, et al.
Seminars in Cancer Biology (2021) Vol. 86, pp. 998-1013
Closed Access | Times Cited: 64
Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma
Auris Huen, Bradley M. Haverkos, Jasmine M. Zain, et al.
Cancers (2020) Vol. 12, Iss. 8, pp. 2293-2293
Open Access | Times Cited: 58
Newly Developed Prodrugs and Prodrugs in Development; an Insight of the Recent Years
Anas Najjar, Abderrahman Najjar, Rafik Karaman
Molecules (2020) Vol. 25, Iss. 4, pp. 884-884
Open Access | Times Cited: 57
Current Methods of Post-Translational Modification Analysis and Their Applications in Blood Cancers
Katie Dunphy, Paul Dowling, Despina Bazou, et al.
Cancers (2021) Vol. 13, Iss. 8, pp. 1930-1930
Open Access | Times Cited: 49
Epigenetic modifications in obesity‐associated diseases
Yiqian Long, Chao Mao, Shuang Liu, et al.
MedComm (2024) Vol. 5, Iss. 2
Open Access | Times Cited: 7
Advances in dual-targeting inhibitors of HDAC6 for cancer treatment
Zhicheng Gu, Shuxian Lin, Junhui Yu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 275, pp. 116571-116571
Closed Access | Times Cited: 6
Bioactive peptides from food science to pharmaceutical industries: their mechanism of action, potential role in cancer treatment and available resources
Maryam Bidram, Mohamad Reza Ganjalikhany
Heliyon (2024) Vol. 10, Iss. 23, pp. e40563-e40563
Open Access | Times Cited: 6
Histone Deacetylases and Their Inhibitors in Cancer Epigenetics
Kelly N. Hassell
Diseases (2019) Vol. 7, Iss. 4, pp. 57-57
Open Access | Times Cited: 53
Chromobacterium spp. mediate their anti-Plasmodium activity through secretion of the histone deacetylase inhibitor romidepsin
Raúl G. Saraiva, Callie R. Huitt-Roehl, Abhai K. Tripathi, et al.
Scientific Reports (2018) Vol. 8, Iss. 1
Open Access | Times Cited: 48
Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy
Eftiola Pojani, Daniela Barlocco
Current Medicinal Chemistry (2020) Vol. 28, Iss. 7, pp. 1290-1303
Closed Access | Times Cited: 44
A cyclic peptide inhibitor of the SARS-CoV-2 main protease
Adam G. Kreutzer, Maj Krumberger, Elizabeth M. Diessner, et al.
European Journal of Medicinal Chemistry (2021) Vol. 221, pp. 113530-113530
Open Access | Times Cited: 34
The role of protein acetylation in carcinogenesis and targeted drug discovery
Jingru Yang, Cong Song, Xianquan Zhan
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 27
Molecular mechanisms of histone deacetylases and inhibitors in renal fibrosis progression
Jiayu Wang, Jiaxing Li, Xin Zhang, et al.
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 24
TMP195 Exerts Antitumor Effects on Colorectal Cancer by Promoting M1 Macrophages Polarization
Yicheng Han, Jiachun Sun, Yanyan Yang, et al.
International Journal of Biological Sciences (2022) Vol. 18, Iss. 15, pp. 5653-5666
Open Access | Times Cited: 24
Targeting epigenetic regulation for cancer therapy using small molecule inhibitors
Amit Kumar, Luni Emdad, Paul B. Fisher, et al.
Advances in cancer research (2023), pp. 73-161
Closed Access | Times Cited: 15
Perspectives and new aspects of histone deacetylase inhibitors in the therapy of CNS diseases
Bo Han, Mengfei Wang, Jiayi Li, et al.
European Journal of Medicinal Chemistry (2023) Vol. 258, pp. 115613-115613
Closed Access | Times Cited: 14
Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL)
Guang Lu, Shikai Jin, Su-Wen Lin, et al.
Clinical Epigenetics (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 13
Cyclic peptides: a powerful instrument for advancing biomedical nanotechnologies and drug development
Paul Cristian Martian, Mihaela Tertiş, Denisa Leonte, et al.
Journal of Pharmaceutical and Biomedical Analysis (2024) Vol. 252, pp. 116488-116488
Open Access | Times Cited: 5
Probing into the plasma stability and microsomal stability of thiol-based prodrug derivatives: Using IYS-15, an HDAC inhibitor as the model thiol
Lingxuan Zhu, Zhiyuan Wang, Qingjiao Li, et al.
Bioorganic & Medicinal Chemistry (2025) Vol. 119, pp. 118064-118064
Closed Access
Marine peptides in lymphoma: surgery at molecular level for therapeutic understanding
Salman Ahmed, Michael Aschner, Khalaf F. Alsharif, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
Discovery of HDAC6-Selective Inhibitor NN-390 with in Vitro Efficacy in Group 3 Medulloblastoma
Nabanita Nawar, Shazreh Bukhari, Ashley Adile, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 4, pp. 3193-3217
Closed Access | Times Cited: 21
Page 1 - Next Page

Scroll to top